TriBiotica is pioneering a novel therapeutic approach to cancer treatment through its Haplomer™ technology platform, which leverages the principles of immunotherapy to target a wide range of cancer types. This innovative platform utilizes tumor-specific gene signatures to create unique building blocks known as Haplomers, which are assembled within cancer cells. By doing so, Haplomers enable the development of targeted immunotherapies that can effectively distinguish between cancerous and healthy cells, minimizing potential side effects associated with traditional treatments. The technology addresses a significant challenge in cancer therapy: the lack of specific markers on tumor cells that can be targeted without affecting normal cells.

The Haplomer technology operates by utilizing a pair of compounds that require a specific genetic sequence found in tumor cells for activation. When both components of the Haplomer pair bind to this triggering RNA, they react to produce an activated marker that can engage therapeutic antibodies or T-cell receptors, leading to the destruction of the tumor cells. This mechanism not only enhances the specificity and safety of cancer treatments but also allows for flexibility in targeting various genetic markers, including non-coding RNAs. The platform's modular design enables the rapid adaptation of therapies to target previously untreatable cancer types, making it a promising advancement in the field of cancer immunotherapy.

United States

Developing immnotherpies based on haplomers. Haplomers are unique building blocks that are assembled within cancer cells to create an active therapeutic without harming healthy cells. They produce new markers specifically on tumor cells, with genetic precision.

TriBiotica

Company Details